Minerva Neurosciences Inc (NERV)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $114.62M
Last updated: Nov 17, 2026 at 11:06 AM ET
Minerva Neurosciences Inc (NERV) Stock Forecast
Analysts expect Minerva Neurosciences (NERV) to earn -$0.54 per share in the fiscal year ending Dec 31, 2026. Of 3 analysts, 2 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 33.3% |
| Buy | 1 | 33.3% |
| Hold | 1 | 33.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$0.54
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.42
- EPS consensus
- Next report
- Mar 9, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.54 | -$0.54 to -$0.54 | 1 |
| Dec 31, 2027 | -$0.42 | -$0.42 to -$0.42 | 1 |
Quarterly Estimates
The EPS consensus rises from -$0.14 for the quarter ending Dec 31, 2026 to -$0.09 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.14 | -$0.24 to -$0.01 | 5 |
| Mar 31, 2027 | -$0.09 | -$0.09 to -$0.09 | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.57.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.54 | -$0.57 | -$0.57 | -$0.57 | -$0.57 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.42 | -$0.42 | -$0.42 | -$0.42 | -$0.42 | N/A |
| Quarter ending Mar 31, 2027 | -$0.09 | N/A | N/A | N/A | -$0.11 | N/A |
Frequently Asked Questions About NERV
What is the NERV stock forecast?
Consensus analyst estimates put Minerva Neurosciences's EPS at -$0.54 for the fiscal year ending Dec 31, 2026. The consensus rating from 3 analysts is Buy.
How do analysts rate NERV stock?
Of 3 analysts covering Minerva Neurosciences, 1 rates it Strong Buy, 1 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from NERV next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.54, with estimates from -$0.54 to -$0.54 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.42, with estimates from -$0.42 to -$0.42 from 1 analyst.
How many analysts cover NERV?
3 analysts rate Minerva Neurosciences stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
NERV pages: Overview, Earnings, Forecast, Financials, Competitors